Evidence map›Paper›PMID 38969996›Full record

ArticleBMC cardiovascular disorders2024

Analytical and clinical performance evaluation of a new NT-proBNP assay.

Pingfeng Feng, Junlong Qin, Zhixin Chai, Yajie Zhang, Minghai Zhao, Liya Liu, Lijun Zhang, Yaqiong Chen, Yufeng Xiong

Abstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pingfeng Feng *Department of Medical Laboratory, Nanfang Hospital Southern Medical University, No.1838, Guangzhou Avenue North, Guangzhou, 510515, China.
Junlong Qin *Medical Laboratory of ShenzhenLuohu Hospital Group, Shenzhen, 518005, China.
Zhixin ChaiDepartment of Medical Laboratory, Nanfang Hospital Southern Medical University, No.1838, Guangzhou Avenue North, Guangzhou, 510515, China.
Yajie ZhangDepartment of Medical Laboratory, Nanfang Hospital Southern Medical University, No.1838, Guangzhou Avenue North, Guangzhou, 510515, China.
Minghai ZhaoDepartment of Medical Laboratory, Nanfang Hospital Southern Medical University, No.1838, Guangzhou Avenue North, Guangzhou, 510515, China.
Liya LiuMedical Laboratory of ShenzhenLuohu Hospital Group, Shenzhen, 518005, China.
Lijun ZhangMedical Laboratory of ShenzhenLuohu Hospital Group, Shenzhen, 518005, China.
Yaqiong ChenMedical Laboratory of ShenzhenLuohu Hospital Group, Shenzhen, 518005, China.
Yufeng XiongDepartment of Medical Laboratory, Nanfang Hospital Southern Medical University, No.1838, Guangzhou Avenue North, Guangzhou, 510515, China. xiongyufengnh@126.com.

Funding

Guangdong Province Key Field R&D Plan Project 2020B1111160001
6 · The paper itself

Abstract

backgroundThe study evaluated the performance of the Mindray N-terminal pro-B-type natriuretic peptide (NT-proBNP) in a healthy population in China, focusing on creating a reference range for future clinical applications adjusted according to different demographics.

methodsThe study measured NT-proBNP in 2277 healthy individuals. We analyzed age and sex-stratified data, performed precision, accuracy, linearitcvy, and detection limit studies, and evaluated method comparison and consistency between Roche and Mindray assays on 724 serum samples. We used Excel 2010, Medcalc, and GraphPad Prism 9.

resultsIn males, the 97.5th centile NT-proBNP concentration at age < 45, 45 to 54, 55 to 64, 65 to 74 and ≧ 75 were 89.4 ng/L, 126 ng/L, 206 ng/L, 386 ng/L and 522 ng/L, respectively. In females, the concentration of NT-proBNP at the same age was 132 ng/L, 229 ng/L, 262 ng/L, 297 ng/L and 807 ng/L, respectively. The repeatability precision coefficient of variation (CV%) for NT-proBNP was between 0.86 and 1.65 in analytical performance. In contrast, the reproducibility precision (CV%) for NT-proBNP was between 1.52 and 3.22, respectively. The study found a bias of accuracy of 3.73% in low-value samples (concentration: 148.69) and 7.31% in high-value samples (concentration: 1939.08). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 125 ng/L were 96.6%, 92.3%, 84.2%, and 98.5%, respectively. In contrast, those of 300 ng/L were 94.0%, 98.2%, 95.7% and 97.5%, respectively.

conclusionsThe Mindray NT-proBNP assay showed increased levels in both males and females with age, with higher levels in women. It performs well and aligns with manufacturer specifications. We recommend adjusting cutoff values based on demographic factors.

Indexed as

BiomarkersNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsAdultAgedAged, 80 and overAge FactorsChinaFemaleHealthy VolunteersHumansLimit of DetectionMaleMiddle AgedReference ValuesBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)NT-proBNPPerformance verificationReference range

Identifiers

PMID38969996
PMCPMC11229486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.